Anti-m antibody in solid tumors-two case reports.

Area of Science:

• Immunology
• Transfusion Medicine
• Oncology

Background:

• Anti-M antibodies are typically immunoglobulin M (IgM), act as cold agglutinins, and are generally considered clinically insignificant.
• Their clinical relevance is often underestimated in routine blood banking procedures.

Observation:

• Two cases of anti-M antibodies were identified in patients with solid tumors.
• These antibodies led to discrepancies in blood grouping results.
• The anti-M antibodies reacted during the Coombs phase of crossmatching procedures.

Findings:

• In one case, the anti-M antibody exhibited a dosage effect, indicating varying antibody strength.
• The presence of anti-M antibodies in the Coombs phase suggests a potential for clinically significant immune responses.
• This challenges the traditional view of anti-M as solely insignificant.

Implications:

• Anti-M antibodies can be clinically significant, particularly when detected in the Coombs phase.
• Transfusion of M antigen-negative, Coombs-negative blood units is crucial for patients with these antibodies.
• This highlights the need for careful antibody screening and characterization in transfusion medicine, especially in oncology patients.